alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Gut, metabolism and diet

1,048 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. A Physicist's Perspective on Metabolic Rejuvenation After 50

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-09-09 Brain scans and imaging

    Chronic metabolic diseases, including Type 2 Diabetes, hypertension, non-alcoholic fatty liver disease (NAFLD), prostate enlargement, musculoskeletal joint friction, cardiac arrhythmias, neurodegenerative waste accumulation (Alzheimer's), and elevated intraocular hydraulic pressure (glaucoma), are frequently treated as distinct, unavoidable consequences of chronological aging.

  2. Neuroprotective potential of Acetylcholinesterase Inhibitors from Natural Sources in Combating Neurodegenerative Diseases

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. ScienceOpen Preprints 2026-09-08 Disease mechanisms

    Neurodegenerative diseases comprise a diverse group of progressive disorders characterized by the selective and irreversible loss of neuronal structure and function within the specific regions of the central and/or peripheral nervous systems.

  3. Synergistic Nano-Architectures: How Date Seed Phytochemicals and Cellulose Matrices Template Silver Nanoparticles for Multifunctional Therapy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-07 Treatments

    This study reports the eco-friendly green synthesis of a multifunctional silver nanocomposite (DS-MC-Ag-nanocomposite) utilizing ethanolic extract of waste date seeds ( Phoenix dactylifera ) and methyl cellulose (MC) as dual reducing and stabilizing agents.

  4. Bee Venom-Loaded Nanoliposomes as an Antioxidant and Erythroprotective Delivery Platform for In Vitro Controlled Release and Improved Gastrointestinal Stability

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-09-07 Disease mechanisms

    Bee venom (BV) contains bioactive peptides with potent antioxidant, anti-inflammatory, and neuroprotective properties, yet its direct therapeutic use is limited by cytotoxicity, instability, and uncontrolled release.

  5. Postmortem Alterations of Metabotropic Glutamate Receptors across Neuropsychiatric Disorders: A Systematic Review

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-09-03 Prevention and risk

    Metabotropic glutamate receptors (mGluRs) regulate glutamatergic transmission and have been implicated in diverse neuropsychiatric disorders, but human postmortem evidence remains fragmented.

  6. The Gut-Brain Axis in Alzheimer’s Disease: Microbiota as a Key Contributor to Disease Pathogenesis

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-08-31 Disease mechanisms

    Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder influenced by genetic, environmental, and lifestyle factors.

  7. Low-dose lithium prevents age-dependent metabolic stress–driven alzheimer’s disease–like pathology through restoration of the NAMPT–NAD⁺–SIRT1–AMPK–TFEB metabolic resilience network

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-26 Drug development

    These findings identify an age-dependent breakdown of the metabolic resilience network formed by NAMPT, NAD⁺, SIRT1, and AMPK as a key mechanistic driver of metabolic stress-induced early AD-like pathology.

  8. Autophagy Stimulation by Intermittent Fasting and Its Potential Neuroprotective Role in Alzheimer’s Disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-08-24 Risk factors

    Alzheimer’s disease (AD) is characterised by progressive accumulation of misfolded proteins and failure of cellular clearance pathways, particularly the autophagy–lysosomal system.

  9. Semaglutide Activates the Orexin/Hypocretin and Basal Forebrain Cholinergic Systems and Increases Acetylcholine Levels in the Hippocampus of Young and Aged Rats

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-08-06 Drug development

    GLP-1 agonist drug repurposing efforts may establish new clinical niches in managing psychiatric and neurological disorders.

  10. Gut microbiota mediates the association between aging and cognitive function: evidence from a population-based Kyotango study linking diet, Bifidobacterium, and Mini-Mental State Examination (MMSE) score

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-04 Disease mechanisms

    Our findings provide evidence that age-related changes in the gut microbiota, particularly reductions in Bifidobacterium , partially mediate cognitive decline in older adults.

  11. The Gut-Brain Axis Mechanism in Alzheimer’s Disease: From Animal Models to Clinical Translation and Innovative Treatment Strategies

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-07-30 Disease mechanisms

    Research on gut microbiota in Alzheimer’s disease (AD) has progressed from observational correlations to the validation of causal relationships.

  12. The Effects of a Multidomain Lifestyle Intervention on Brain Function and Its Relation with Immunometabolic Markers and Intestinal Health in Older Adults at Risk of Cognitive Decline: The HELI Randomised Controlled Trial

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-07-29 Clinical trials

    We investigated brain, inflammation, cardiometabolic, and gut health changes associated with a six-month multidomain lifestyle intervention in Dutch older adults at risk for cognitive decline and dementia.

  13. Common Dysregulated Pathways and Genes in Alzheimer’s, Parkinson’s, and Huntington’s Diseases: A Computational Analysis to Nominate Candidate Gene Targets for Drug Repurposing

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-07-25 Drug development

    Neurodegenerative diseases are a major threat to older adults and represent a growing global health burden as the elderly population continues to expand.

  14. Decreased Plasma IGF-1 Is Associated with Cortical Atrophy, But Not Concomitant Cerebrovascular Disease in Alzheimer’s Dementia

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-07-24 Biomarkers

    Dysregulated insulin signaling in brain has been linked to cognitive impairment and dementia.

  15. The Ocular Microbiome and Alzheimer’s Disease: Emerging Insights

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-07-22 Disease mechanisms

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β plaques, neurofibrillary tau tangles, neuroinflammation, and progressive cognitive decline.

  16. Network Pharmacology and Molecular Docking Uncover Novel Candidate Compound-Target Actions of Yokukansan (Yi-Gan San) in the Behavioral and Psychological Symptoms of Dementia

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-07-21 Clinical safety

    In total, 45 constituents were mapped to 181 human target genes through measured compound-target edges.

  17. Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-07-17 Drug development

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have moved rapidly from metabolic medicine into neurology, but the evidence to mid-2026 refuses to resolve into a single narrative of neuroprotection.

  18. Phenolic chemotypic diversity in Tunisian Hertia cheirifolia populations: influence of plant organs and phenological stages on antioxidant and anti-acetylcholinesterase activities

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-07 Treatments

    H. cheirifolia phenolic extracts exhibit potent, mechanism-specific antioxidant activity and promising AChE inhibition, validating traditional use in neurological complaints.

  19. Development of a metabolomics-based index to monitor dietary effects on chronic inflammation: The Dietary Metabolomics Inflammation Index

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-07-06 Prevention and risk

    DMII provides a metabolomics-based framework for assessing diet-related chronic inflammation using metabolomics data.

  20. Alterations of gut microbiota in Down syndrome and their association with Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-04-04 Down syndrome and Alzheimer's

    Structured Abstract INTRODUCTION Adults with Down syndrome (DS) have a higher risk of developing Alzheimer’s disease (AD).

  21. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-12-02 Drug development

    Among adults with obesity or overweight with a weight related condition, there was no difference in the risk of PD or Parkinsonian disorders between GLP-1 RA users and non-users.

  22. RETRACTED: Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease

    ⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. International journal of molecular sciences 2021-01-16 Drug development

    Recent clinical and epidemiological studies support the contention that diabetes mellitus (DM) is a strong risk factor for the development of Alzheimer's disease (AD).

  23. CircNF1-419 improves the gut microbiome structure and function in AD-like mice

    ⚠ Retracted — do not rely on it alzhub usefulness score 12 out of 100. Aging 2020-01-06 Disease mechanisms

    Our pre-experiments found that the brain circRNA sequence profiles and gut microbiota in AD-like mice were changed, as circNF1-419 could enhance autophagy to ameliorate senile dementia in AD-like mice, so we conclude that there might some connections between circRNA and gut microbiome.

From across this topic

9 of the 1,048 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

Other topics